GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) Financial Statements
Historical financial data — 5 statements covering FY2021–FY2025
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines...
GSK plc American Depositary Shares (Each representing two Ordinary Shares)'s revenue increased 4.1% year over year, from $31.38B to $32.67B.
Net income increased 122.0% over the same period, from $2.58B to $5.72B.
Over the 4-year period from FY2021 to FY2025, revenue grew by 32% in total.
Total debt remained relatively stable at $17.72B.
The debt-to-equity ratio stands at 1.11, indicating a elevated leverage profile.
GSK plc American Depositary Shares (Each representing two Ordinary Shares) maintains a healthy net profit margin of 17.5%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2021 | $24.70B | $4.38B | $16.53B | $4.36B | N/A | $79.10B | $24.17B | $21.34B |
| FY2022 | $29.32B+18.7% | $14.96B | $19.77B | $6.43B | N/A | $60.15B | $20.99B | $10.10B |
| FY2023 | $30.33B+3.4% | $4.93B | $21.76B | $6.75B | N/A | $59.01B | $18.02B | $12.79B |
| FY2024 | $31.38B+3.5% | $2.58B | $22.33B | $4.02B | N/A | $59.46B | $16.99B | $13.09B |
| FY2025 | $32.67B+4.1% | $5.72B | $23.65B | $7.93B | N/A | $61.12B | $17.72B | $15.96B |